Latest Conference Articles

HRV-induced cytokine responses were reduced in patients with severe asthma.

Pulmonary conditions like asthma could often lead to the development of chronic cough.

Despite not being able to attend conferences live, there are some advantages to a virtual conference.

The molecular mechanisms of steroid resistance suggest the P13K/Akt signaling pathway and the MAPK signaling pathway are involved.

New cohort analysis shows an over-reliance on therapy designed as an add-on for asthma control.

Twelve-year data shows patients without control of their asthma could suffer lung failure quickly if they aren't consistent in maintenance therapy.

Asthma patients have not had higher rates of negative outcomes from COVID-19 than other individuals.

The biologic drug is set to be used as a combination therapy for asthma.

In a study presented at ERS, researchers IOS could be used for assessment level of asthma control in both adult and pediatric patients.

Patients saw improvement in symptom perception, activity limitation, emotional function, and environmental stimuli.

It has been approximately 60 years since a new treatment for coughs has come on the market.

Data shows certain personality traits are linked to a COPD patient's likelihood of active or sedentary behaviors.

The added indication makes the GSK single inhaler triple therapy the first of its kind approved for both asthma and COPD in the US.

Telemedicine has become an important tool during the COVID-19 pandemic.

Problems using inhalers correctly is an ongoing issue for both pediatric and adult patients.

New ERS findings show patients hospitalized for COVID-19 bettered from timelier, personalized rehabilitation plans.

A $25 genetic test could inform physicians on optimal controller therapy for children and adolescents with asthma.

In a new study presented at ERS 2020, Dr. Mark Levy discusses how a digital inhaler reduces the amount of people who use their inhaler incorrectly.

The risk of cardiovascular hospitalizations was associated with increasing PM10 at lag 0.

Manan Pareek, MD, PhD gives an overview about what is currently known about COVID-19 and cardiovascular risk.

In a poster presented at ERS, researchers find the complement and coagulation cascades pathway was up-regulated in response to airway presence of Moraxella genera that might suggest an activation of systemic innate immunity in response to Moraxella.

Three patients with unclassified interstitial lung disease had a change in diagnosis during the study’s follow-up period.

Of the 2199 patients who received a renal transplant, only 8 were treated for active tuberculosis.

In a poster presented at the ERS Virtual Conference, investigators identify the relative rate of severe asthma exacerbations using LAMA monotherapy.

Investigators report on a post-hoc analysis of the EMPA-REG OUTCOME trial that assesses the efficacy of the SGLT-2 inhibitor in patients with obstructive sleep apnea.

These guidelines set by ESC and EAS 2019 established treatment goals for LDL-C, non-HDL-C, and Apo-B in patients at high risk for cardiovascular disease.

The new equation model has shown to be more accurate than the Framingham Lifetime Risk equation and Pooled Cohort Equation.

Post hoc analysis of REAL-CAD shows the cholesterol metric does not serve to inform statin treatment control of coronary artery disease.